Improving Healthcare Delivery: The FDA and CMS Policy Alignment for Cardiovascular Devices

By Staff Writer

November 2, 2023

Navigating the FDA and CMS Policy Alignment

Two of the most important pillars supporting the healthcare sector are the Food and Drug Administration (FDA) of the United States and the Centers for Medicare & Medicaid Services (CMS). The FDA is in charge of ensuring that medical devices are both safe and effective. The coverage and benefits that are provided to CMS’s beneficiaries are decided by CMS. Because of the different legislative authorities held by these two agencies, the regulatory environment that medical device manufacturers must operate in is quite complicated.

One such program run by the FDA is called the Breakthrough Devices Program, or BDP for short. Its purpose is to encourage innovation by bestowing Breakthrough designations early on in the process of device development in order to speed up the approval process for market release. This strategy is flexible enough to accommodate a higher degree of ambiguity regarding the benefits and risks involved, provided sufficient postmarket evidence is gathered.

 

The BDP’s Impact on Healthcare Costs and Innovation

The healthcare sector has been profoundly affected as a result of the BDP’s initiatives. Since the year 2020, devices that have been given the Breakthrough designation have, in effect, automatically qualified to receive supplementary Medicare reimbursement. This change came about as a result of CMS’s decision to relax a long-standing requirement that medical devices demonstrate “substantial clinical improvement” for the people they serve (the beneficiaries).

However, the BDP’s strategy has not been without of difficulties throughout its history. The BDP might make it possible for the FDA to grant approval based on evidence that isn’t quite as stringent, including single-arm trials that focus on surrogate end goals and only have short-term follow-up. Because of this strategy, several medical devices have been granted approval based on evidence that may not be typical of Medicare recipients as a whole.

There is a significant opportunity for the BDP to serve as a catalyst for innovation in the healthcare sector. On the other hand, this raises a number of issues in terms of ensuring that the highest quality evidence is provided to guide clinical care. In order to maintain this equilibrium, the FDA and CMS will need to continue to collaborate on the improvement of their respective rules and procedures.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.